About FRAS1-related extracellular matrix protein 3
FRAS1-related extracellular matrix protein 3 (FREM3) is a protein
from Homo sapiens identified by UniProt accession
P0C091, 2139 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | FRAS1-related extracellular matrix protein 3 |
|---|
| UniProt accession | P0C091 |
|---|
| Gene | FREM3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2139 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (49)
Diseases linked to this target (Open Targets).
- HbA1c measurement · score 0.25
- mean corpuscular volume · score 0.15
- chronic obstructive pulmonary disease · score 0.14
- leukocyte count · score 0.14
- mean reticulocyte volume · score 0.13
- Red cell distribution width · score 0.13
- platelet crit · score 0.12
- smoking status measurement · score 0.12
- bilirubin measurement · score 0.10
- neutrophil count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0C091-F1 | alphafold | PREDICTED | 75.70 | — |
Amino-acid sequence (2139 residues)
MAGASRHPTG TPRQLLVALA CLLLSRPALQ GRASSLGTEP DPALYLPARG ALDGTRPDGP SVLIANPGLR VPLGRSLWLD PLRDLVIGVQ PGDRCEVTVL DALPRLKGAL SPRRFPCTFG PRQVQYTHFG SHSPGRARVL LQLRYDAPTH TLVLPFTLAV DLVFSQLELV TRNRPLVVEK LRSWSRAIDR RVLDFASLKS GATATRRCRL TPLPHEDGPL PKYGRLVDAV GAPLPRGKGV DCEAFLRAGV RYQHTATSSP NRDYVPMMVE LLGPEGQDAG SAGVLVREHF QLLVRIRGGA ENTPPRPSFM ATMMMEVDPL VLTALTPDAL AAEDVESDPG DLVFNILNAP THPPGHPGQQ GYVVSTDDPL GLPVSFFTQQ ELRELKIAYQ PPAENSHGER LFQLELEVVD GDGAASDPFA FMVTVKSMNT LVPVASHNRG LVLFEGQSRP LSSTHSIPIS DKDNLEEVKM AAVRGLRHGQ LVVFGAPAGC KYFTPADLAA GRVVYQHDGS NTYSDNIIFR MEDGHHQVDF LFPLTILPVD DEPPMVNTNT GLSLTEGQVV QISPFVLSAT DIDSEDSTIH FVLENQPLKG NEEEPQWELA PGSSHSGHYL GDLLLQQAEL PLSTEDEDWH YMEKEGLYEK VVTEWLQRDI MEGRLFYRHL GPHSPQSVMV QLAFHVQDDH DPPNLSKQHI FTIKVQPVDI LSPQLYPGTT LEMTVQEYQL THFQKNFLRY IDQDSDDQNL WYTLLTLPTD TDGNHQVRAG EIVLTDSPDT LIMHFTQAQV NQHKVAYQPP QKLGIAPRVV QFTYQVEDAA GNSVPGTFTL FLQPVDNQPP EVTNRGFAIL EGGSFNLSSN ELHVTDPDTD IDQIVFILVR GPQHGHLQYF KRCMVPGESF MQADVINGSV SYQHGRDQTT TSDTFHLEVS DGVHHIPITI PISVHPNVAN RSPRISLRSS SLLDVSIDVL ENKATEITMG VIHGKRKDVG DLMLSFIVKD SPKLGTILVN GLPTERFTQE DLINGRVAYA HTAGEVGFQK QHDAFSLILS KDSYQWVVGN SIIEKVQVQV TVLPVDNVGP KVFVGESFIV YEGEKNSLTL QHLHVEDVDT HQDELLCTVT SQPASGYLEK IASAPGSKMS QSGSPISAFS LRDIQVRHIN YVQSIHKGVE PQEDQFTFYC SDGINFSPNV FFPIIILPTN DEQPKLFAHE FKVLEGMSLV IDTQLLNGAD ADLPPNELHF QLTALPRHGR IIQQLATGSQ PIHSFTLKEI QEASTIVYEH DDSETKEDSF EVWLSDGKHT THRKVPIVVT LVDDETPHLT VNNGLKVEKG HSEIITNRIL KATDLDSDDK SLSFVLHSGP QQGLLQRLRK PRGEVRNNLT LGMNFTQDEI NRGLICYIHT GQEGIVDIIK FDVTDGVNTL TDHYFYVTIG NLDSVFPEVI SKRITLIEGA RVTLTNNLLT NSDINSSDEH HFSITRAPSL GHLESSDYAG EPIASFTQLQ LASNKISYVH TSNDEKKMDS FEFQVIGELY PVFRTFRIFI TDVDNKKPIL TIHRLTLQKE DSQLITLLEL TVEDSDTPDD LILFTITQVP MHGKILYNGS RPVTTFTKQD LNKNLISYKH DGSETTEDSF SLTVTDGTHT DFYVLPDTAL ATHKPQVMRV QIRSLDNRLP QITTNRGAPA LKRLHTGHMG FLITSKSLKA EDQDSPHRLL KYKVTRGPEH GFIIKTGLGN QSTRVFTQAD IDEMKISYVL NEGSNASKDI FYFSVEDNGG NKLTNQPFHL NWAWICLEKE YYIVDEDSTF LEVTLTRRGY LGETSFISIG TKDETAKKDK DFKWKTNKQI QFNPGQTTAT WRVRIIPDNE YETSETFQII LSEPLMAVLE FPEMATVEIV DPGDESTVYI PEAEYKIEED IGELLIPVRR SGDASQELIV ICSTRQGSAT GTISSTVLFS DYISRPEDHT SILHFDKNET QKTCQVLIID DSLYEEEESF SVSLRLPVGG QLGARFPTTK VTILADRYDE PVLHFGDAEY HVNESARYVE VCVWRRGTDL SQPSSIAVRS RKSEQESAEA GTDYVGISRN LDFAPGVRMQ TFQVTILDDL GQPTLEGPEK FELLLQMPMG AVLGEPNKTT IFIEDTITDC KQSACSSFD
Explore FRAS1-related extracellular matrix protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets